1M Veterans with Serious Mental Illness Targeted for Psychedelic Therapies Under New Federal Partnership

For healthcare systems and providers, the federal push to integrate psychedelic-assisted therapy represents both a regulatory milestone and a significant workforce challenge. Training thousands of clinicians to safely administer these rapid-acting psychiatric drugs will demand new protocols, infrastructure, and funding, as the VA and HHS aim to turn research into standard care for conditions like PTSD and depression.

On Monday, July 14, 2026, the Department of Health and Human Services (HHS) and the Department of Veterans Affairs (VA) formalized a groundbreaking partnership to accelerate the development and deployment of psychedelic therapies for veterans suffering from serious mental illness. HHS Secretary Robert F. Kennedy, Jr., and VA Secretary Doug Collins signed a memorandum of understanding (MOU) at VA headquarters, implementing President Trump’s Executive Order 14401. The order explicitly directs federal agencies to fast-track research, clinical trials, and interagency coordination for novel rapid-acting psychiatric treatments. Kennedy emphasized the urgency, noting that approximately 1 million veterans currently live with a serious mental illness—a staggering figure that underscores the heavy toll of conditions like PTSD, major depression, and substance use disorders on the veteran population.

“

Kennedy, Jr., and VA Secretary Doug Collins signed a memorandum of understanding (MOU) at VA headquarters, implementing President Trump’s Executive Order 14401.

The MOU outlines four concrete pillars of collaboration. First, both departments will work to increase veteran participation in clinical trials for promising rapid-acting mental health treatments. Second, a large-scale workforce development effort will train therapists, nurses, physicians, and other clinicians to safely administer future FDA-approved rapid-acting psychiatric drug products, addressing a critical bottleneck in the clinical translation of psychedelic medicines. Third, the agencies will jointly collect and share real-world data on safety, effectiveness, and costs to refine patient care protocols and inform future policy. Fourth, they will coordinate research agendas and data sharing to avoid duplication and accelerate the pipeline from laboratory to clinic. This comprehensive approach moves beyond isolated research studies toward building an integrated care infrastructure ready for FDA-sanctioned psychedelic therapies.

The impetus for this initiative stems from a growing body of evidence supporting psychedelic compounds such as psilocybin and MDMA in treating post-traumatic stress disorder and treatment-resistant depression. VA researchers have been at the forefront of several clinical trials, but federal hurdles—including the Schedule I classification of many psychedelics and limited funding—have slowed progress. Executive Order 14401 aims to sweep away bureaucratic obstacles by aligning HHS’s regulatory and public health expertise with the VA’s extensive patient network and research capabilities. The partnership signals a major policy shift: viewing psychedelic-assisted therapy not as a fringe experiment but as a legitimate, potentially life-saving medical tool deserving of full federal support.

From a healthcare market perspective, the MOU catalyzes investment and development in a nascent but rapidly expanding sector. Pharmaceutical companies and biotech startups focusing on psychedelic drug development—such as MAPS Public Benefit Corporation, Compass Pathways, and atai Life Sciences—stand to benefit from clearer regulatory pathways and a guaranteed large-scale purchaser in the VA. However, because these therapies require specialized administration (often involving multi-hour therapy sessions with trained monitors), the rollout will press the VA to build or contract new treatment centers, creating opportunities for telehealth platforms, digital therapeutics, and integrated behavioral health networks. Cost-effectiveness data collected under the partnership will be pivotal in securing Medicare and private insurance coverage down the road.